Optimising Cancer Immunotherapy: Challenges and Opportunities - European Medical Journal
×

Browse

Optimising Cancer Immunotherapy: Challenges and Opportunities

| Download as | PDF
Chairpeople:
Alexander M. M. Eggermont,3 Ignacio Melero4
Speakers:
Joachim G. Aerts,5 Mario Colombo,6 George Coukos,7 Eric Deutsch,3 Thomas Powles8
Disclosure:

Dr Abair has no relevant financial relationships to disclose. Dr Coleman has received research funding to his institution from Bayer and Amgen. Dr Eggermont has received consulting fees from Actelion, Bristol-Myers Squibb, Incyte, Nektar, and Sanofi. Dr Melero has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Incyte, and Roche. He has performed contracted research for or received research support from Pfizer. Dr Aerts has received consulting fees from Bristol-Myers Squibb, AstraZeneca, MSD, Roche, Eli Lilly, and Boehringer Ingelheim. He has performed contracted research or received research support from Eli Lilly and Roche. He has received fees for non-CME services from AstraZeneca. He has ownership interest in Amphera and is in receipt of intellectual property rights or is a patent holder for Amphera dendritic cell immunotherapy. Dr Colombo has no relevant financial relationships to disclose. Dr Coukos has received consulting fees from Genentech, Novartis, Roche, and Sanofi-Aventis. He has received fees for non-CME services from Celgene and Boehringer Ingelheim. Dr Deutsch has received consulting fees from Eisai and Merck. He has performed contracted research or has received research support from AZD, Genentech, Lilly, Roche, and Servier. Dr Powles has received consulting fees from Bristol-Myers Squibb, Eisai, and Merck. He has performed contracted research or received research support from AstraZeneca and Roche. Dr Becker has received consulting fees from Amgen, Bristol-Myers Squibb, CureVac, MerckSerono, Rigontec, and Roche. He has also performed contracted research or received research support from Bristol-Myers Squibb and MerckSerono. Dr Blank has received consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Lilly, MSD, Novartis, Pfizer, and Roche. He has also performed contracted research or has received research support from Novartis. Dr Kiessling has received consulting fees from Bristol-Myers Squibb and Immunicum AB. He has performed contracted research of received research support from Immunicum AB. He is also a board member for CLS AB. Dr Maio has no relevant financial relationships to report. Dr Schuler has received consulting fees from Alexion, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, IQWig, Lilly, Novartis, and Pfizer. He has performed contracted research for or received research support from Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis.

Acknowledgements:

Editorial assistance was provided by Trudy Grenon Stoddert, ELS, of prIME Oncology.

Support:

This educational activity is supported by a grant from Incyte Corporation.

Citation
EMJ. ;1[3]:26-43.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Cancer immunotherapy has moved to the forefront in the treatment of patients with cancer, providing a unique opportunity to achieve dramatic and lasting anti-tumour responses in a variety of tumour types. When it comes to patient selection and development of novel immunotherapeutic agents and combinations, so far we have merely scratched the surface of this therapeutic approach. Leading experts in the field of cancer immunotherapy gathered in Amsterdam, Netherlands, on 21st May 2016 for a Scientific Exchange to discuss the current status of immunotherapy within the field of oncology and explore the future of this evolving therapeutic strategy. Current challenges and limitations regarding the use of immunotherapy were addressed for tumour types such as melanoma, lung cancer, bladder cancer, and renal cell carcinoma (RCC). Recent advances and future directions in the areas of immunotherapy biomarkers and mechanisms of resistance were also examined. Current evidence for combination strategies with immunotherapy was highlighted, including combinations with other immunotherapies or with radiotherapy. Below is a summary of the key points discussed during this scientific exchange.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.